艾滋病合并结核病治疗进展:最新治疗指南及文献综述  

Advances in the treatment of AIDS complicated with tuberculosis:a review of the latest guidelines and literatures

作　　者：杨祖群 齐唐凯[2] 卢洪洲[2] Yang Zuqun;Qi Tangkai;Lu Hongzhou(Department of Pediatrics,the People’s Hospital of Butuo County,Yi Autonomous Prefecture of Liangshan,Sichuan Liangshan 616350,China;Department of Infection and Immunity,Shanghai Public Health Clinical Center,Shanghai 201508,China)

机构地区：[1]四川省凉山彝族自治州布拖县人民医院儿科,四川凉山616350 [2]上海市公共卫生临床中心感染与免疫科,上海201508

出　　处：《上海医药》2018年第23期27-30,82,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：结核病是我国艾滋病患者发病和死亡的首要原因。对艾滋病患者的敏感结核杆菌感染治疗,国内外的主要治疗指南的推荐总体一致,但对耐异烟肼单药的结核病的治疗建议略有差异。WHO于2018年大幅更新了对耐多药结核病的治疗建议,推荐了无注射剂的长程治疗方案和短程治疗方案,并对艾滋病毒感染患者使用短程治疗方案作出了明确的规定。同时使用抗反转录病毒药物和抗结核药物治疗时需注意药物相互作用。Tuberculosis is the leading cause of morbidity and mortality among AIDS patients in China.For AIDS patients with susceptible tuberculosis infection,recommendations from the domestic and international guidelines are generally consistent.For isoniazid-resistant tuberculosis,there are slight differences in different guidelines.WHO has markedly updated its recommendations for the treatment of multidrug-resistant tuberculosis,recommending the long-term and short-term treatment without injections and also made clear regulations for HIV-infected patients using short-term treatments.Special attention should be paid to drug interactions when antiretroviral therapy and anti-tuberculosis treatment are co-administered.

关 键 词：人免疫缺陷病毒 艾滋病 结核病 耐多药结核病药 物相互作用 

分 类 号：R512.91[医药卫生—内科学] R52[医药卫生—临床医学]